Angiogenesis in cancer, vascular, rheumatoid and other disease.
Recent discoveries of endogenous negative regulators of angiogenesis, thrombospondin, angiostatin and glioma-derived angiogenesis inhibitory factor, all associated with neovascularized tumours, suggest a new paradigm of tumorigenesis. It is now helpful to think of the switch to the angiogenic phenotype as a net balance of positive and negative regulators of blood vessel growth. The extent to which the negative regulators are decreased during this switch may dictate whether a primary tumour grows rapidly or slowly and whether metastases grow at all.
Folkman
J
J
Children's Hospital, Boston, Massachusetts, USA.
D043168:Angiostatins; D000818:Animals; D001172:Arthritis, Rheumatoid / Q000503:physiopathology; D016228:Endothelial Growth Factors / Q000502:physiology; D005123:Eye / Q000098:blood supply; D006801:Humans; D008222:Lymphokines / Q000502:physiology; D051379:Mice; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000098:blood supply; D009389:Neovascularization, Pathologic; D010446:Peptide Fragments / Q000627:therapeutic use; D010958:Plasminogen / Q000627:therapeutic use; D011565:Psoriasis / Q000503:physiopathology; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D010446:Peptide Fragments; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D043168:Angiostatins; D010958:Plasminogen